PLK3 1-334-pEGFP Citations (2)

Originally described in: Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions.
Yang Y, Bai J, Shen R, Brown SA, Komissarova E, Huang Y, Jiang N, Alberts GF, Costa M, Lu L, Winkles JA, Dai W Cancer Res. 2008 Jun 1. 68(11):4077-85. PubMed Journal

---

Articles Citing PLK3 1-334-pEGFP

Articles
Efficient modification of alpha-synuclein serine 129 by protein kinase CK1 requires phosphorylation of tyrosine 125 as a priming event. Kosten J, Binolfi A, Stuiver M, Verzini S, Theillet FX, Bekei B, van Rossum M, Selenko P. ACS Chem Neurosci. 2014 Dec 17;5(12):1203-8. doi: 10.1021/cn5002254. Epub 2014 Oct 22. PubMed
The role of polo-like kinase 3 in the response of BRAF-mutant cells to targeted anticancer therapies. Babagana M, Kichina JV, Slabodkin H, Johnson S, Maslov A, Brown L, Attwood K, Nikiforov MA, Kandel ES. Mol Carcinog. 2020 Jan;59(1):5-14. doi: 10.1002/mc.23123. Epub 2019 Sep 30. PubMed

If you have published an article using this material, please email us at to have your article added to this page.